Mary Coleman
Investor Relations Contact chez CATALYST PHARMACEUTICALS, INC.
Profil
Mary Coleman is currently the Head-Investor Relations Contact at Catalyst Pharmaceuticals, Inc. She previously worked as the Senior Director-Investor Relations at Savient Pharmaceuticals, Inc., Vice President-Investor Relations & Communications at BioDelivery Sciences International, Inc., Head-Investor Relations at Agile Therapeutics, Inc., and Vice President-Investor Relations at BioXcel Therapeutics, Inc. Ms. Coleman completed her undergraduate degree at Bowling Green State University.
Postes actifs de Mary Coleman
| Sociétés | Poste | Début |
|---|---|---|
| CATALYST PHARMACEUTICALS, INC. | Investor Relations Contact | 16/08/2021 |
Anciens postes connus de Mary Coleman
| Sociétés | Poste | Fin |
|---|---|---|
| BIOXCEL THERAPEUTICS, INC. | Investor Relations Contact | - |
| AGILE THERAPEUTICS, INC. | Investor Relations Contact | - |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | Investor Relations Contact | - |
| SAVIENT PHARMACEUTICALS INC | Investor Relations Contact | - |
Formation de Mary Coleman
| Bowling Green State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AGILE THERAPEUTICS, INC. | Health Technology |
| CATALYST PHARMACEUTICALS, INC. | Health Technology |
| BIOXCEL THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
BioDelivery Sciences International, Inc.
 BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. | Health Technology |
